Acurx Pharmaceuticals, Inc.
Nasdaq · CIK 0001736243 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-1.7M
Net Income
$-1.7M
Eps Basic
-0.62
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-1.7M | - | - |
| Net Income | $-1.7M | - | - |
| Eps Basic | -0.62 | - | - |
| Eps Diluted | -0.62 | - | - |
| Total Assets | $9.5M | - | - |
| Total Liabilities | $2.5M | - | - |
| Shareholders Equity | $7.0M | - | - |
| Operating Cash Flow | $-1.4M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Acurx Pharmaceuticals, Inc. | 2026-05-11 | 0001104659-26-058631 |
| 10-K | Acurx Pharmaceuticals, Inc. | 2026-03-12 | 0001104659-26-027052 |
| 10-Q | Acurx Pharmaceuticals, Inc. | 2025-11-12 | 0001104659-25-109698 |
| 10-Q | Acurx Pharmaceuticals, Inc. | 2025-08-11 | 0001558370-25-011045 |